Forest Labs's most recent trend suggests a bullish bias. One trading opportunity on Forest Labs is a Bull Put Spread using a strike $95.00 short put and a strike $90.00 long put offers a potential 6.38% return on risk over the next 23 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $95.00 by expiration. The full premium credit of $0.30 would be kept by the premium seller. The risk of $4.70 would be incurred if the stock dropped below the $90.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Forest Labs is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Forest Labs is bullish.
The RSI indicator is above 80 which suggests that the stock is in overbought territory.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Forest Labs
8:01 am Forest Labs submits a New Drug Application for Nebivolol and Valsartan combination in Hypertension
Thu, 27 Feb 2014 21:57:01 GMT
Mylan soars to 52-week high after saying ‘poised' for transaction
Thu, 27 Feb 2014 17:04:04 GMT
Forest Laboratories Submits a New Drug Application for Nebivolol and Valsartan Combination in Hypertension
Thu, 27 Feb 2014 13:03:49 GMT
noodls – NEW YORK–(BUSINESS WIRE)–Forest Laboratories, Inc. (NYSE:FRX) announced that it has submitted a New Drug Application (NDA) to the Food and Drug Administration (FDA) for a fixed dose combination (FDC) …
Forest Labs submits NDA for Nebivolol and Valsartan combination in hypertension
Thu, 27 Feb 2014 13:03:27 GMT
Forest Laboratories Submits a New Drug Application for Nebivolol and Valsartan Combination in Hypertension
Thu, 27 Feb 2014 13:00:00 GMT
Business Wire – Forest Laboratories, Inc. announced that it has submitted a New Drug Application to the Food and Drug Administration for a fixed dose combination of ne
Related Posts
Also on Market Tamer…
Follow Us on Facebook